The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis [Image: see text] ()

BACKGROUND: Standard management in the UK for high-risk stage 1 nonseminoma germ cell tumours of the testis (NSGCTT) is two cycles of adjuvant bleomycin, etoposide (360 mg/m(2)), and cisplatin (BE(360)P) chemotherapy, or surveillance. OBJECTIVE: To test whether one cycle of BE(500)P achieves similar...

Descripción completa

Detalles Bibliográficos
Autores principales: Cullen, Michael, Huddart, Robert, Joffe, Johnathan, Gardiner, Deborah, Maynard, Lauren, Hutton, Paul, Mazhar, Danish, Shamash, Jonathan, Wheater, Matthew, White, Jeff, Goubar, Aicha, Porta, Nuria, Witts, Stephanie, Lewis, Rebecca, Hall, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026695/
https://www.ncbi.nlm.nih.gov/pubmed/31901440
http://dx.doi.org/10.1016/j.eururo.2019.11.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026695/
https://www.ncbi.nlm.nih.gov/pubmed/31901440
http://dx.doi.org/10.1016/j.eururo.2019.11.022

Ejemplares similares